Global Low-Density Lipoprotein Cholesterol Targets for Patients With Acute Coronary Syndrome ― Current Guidelines and Clinical Pathways ―
Open Access
- 25 February 2026
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (3) , 266-273
Abstract
The management of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease, particularly those with acute coronary syndrome (ACS), has evolved significantly. Recent evidence emphasizes the importance of early and intensive LDL-C lowering for reducing recurrent cardiovascular events by stabilizing vulnerable plaques. Global guidelines now advocate for more aggressive LDL-C targets, with a common recommendation of <55 mg/dL for high-risk ACS patients. However, regional variations persist in specific target levels, pharmacologic strategies, and follow-up schedules due to differences in healthcare infrastructure, epidemiology, and risk assessment frameworks. Despite guideline updates, achieving recommended LDL-C levels in real-world practice remains challenging, primarily due to issues like healthcare system limitations, patient adherence, and clinical inertia. Some regions in Japan have established local clinical pathways that demonstrate improvements in attainment of LDL-C targets and clinical outcomes. This article explores the current global LDL-C targets and treatment strategies for ACS patients, aiming to enhance the achievement of optimal LDL-C levels and reduce subsequent adverse events.Keywords
This publication has 51 references indexed in Scilit:
- Learnings from Implementation Strategies to Improve Lipid ManagementCurrent Cardiology Reports, 2025
- Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic ReviewCurrent Therapeutic Research, 2024
- Drug intervention as an emerging concept for secondary prevention in patients with coronary diseaseCardiovascular Intervention and Therapeutics, 2024
- Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational studyAtherosclerosis, 2021
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in AdultsCanadian Journal of Cardiology, 2021
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeJACC, 2020
- Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary SyndromeJACC, 2019
- 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?The American Journal of Medicine, 2016
- Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary InterventionJACC, 2015
- Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary SyndromeJACC, 2009